Related Experiment Video
Updated: Jun 4, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors
Ye-Qin Li1, Zhou Fang1, Wen Zhang1
1College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, PR China.
Abstract:
XPO1 is an influential member of the nuclear transporter protein family. The proteins and RNA transported by XPO1 are related to the occurrence and development of many diseases, including refractory tumor diseases and various viral infectious diseases. XPO1 is upregulated in many malignant tumors and is associated with poor prognosis. This article reviews the anti-tumor and anti-viral mechanisms of XPO1, and summarizes the biomarkers that predict the response to XPO1 inhibitors and the research progress of XPO1 as a biomarker in different diseases. In addition, we also summarize the research status of XPO1 inhibitors, and discuss the structure-activity relationship of preclinical inhibitors targeting XPO1 and the research status of XPO1 inhibitor resistance mechanisms.
Insights
Exportin 1 (XPO1) is crucial in transporting proteins and RNA, impacting diseases like cancer and viral infections. Inhibitors targeting XPO1 show therapeutic potential, with ongoing research into biomarkers and resistance mechanisms.
Area of Science:
- Molecular Biology
- Oncology
- Virology
Background:
- Exportin 1 (XPO1) is a key nuclear transporter protein.
- XPO1 dysregulation is linked to various diseases, including refractory tumors and viral infections.
- Elevated XPO1 levels correlate with poor prognosis in malignant tumors.
Purpose of the Study:
- To review the anti-tumor and anti-viral mechanisms of XPO1.
- To summarize predictive biomarkers for XPO1 inhibitor response.
- To discuss the research progress of XPO1 as a disease biomarker.
Main Methods:
- Literature review of XPO1's role in disease.
- Analysis of biomarkers predicting response to XPO1 inhibitors.
- Summary of preclinical XPO1 inhibitor research, including structure-activity relationships and resistance mechanisms.
Main Results:
- XPO1 plays a significant role in disease pathogenesis.
- Biomarkers for predicting XPO1 inhibitor efficacy are being identified.
- Understanding XPO1 inhibitor resistance is crucial for therapeutic development.
Conclusions:
- XPO1 inhibitors represent a promising therapeutic strategy for cancer and viral diseases.
- Further research into XPO1 biomarkers and resistance mechanisms is warranted.
- XPO1 is a potential therapeutic target and biomarker across multiple disease areas.
More Related Videos
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
